Advertisement
Australia markets open in 2 hours 54 minutes
  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     
  • AUD/USD

    0.6423
    -0.0014 (-0.22%)
     
  • ASX 200

    7,642.10
    +36.50 (+0.48%)
     
  • OIL

    82.56
    -0.13 (-0.16%)
     
  • GOLD

    2,392.50
    +4.10 (+0.17%)
     
  • Bitcoin AUD

    98,969.09
    +3,996.93 (+4.21%)
     
  • CMC Crypto 200

    1,311.43
    0.00 (0.00%)
     

OraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 18, 2021

BETHLEHEM, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2021 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. Eastern (7:00 a.m. Pacific) on Tuesday, May 18, 2021.

In order to access the meeting, a stockholder or a person holding a valid stockholder proxy may go to www.virtualshareholdermeeting.com/OSUR2021 at least five (5) minutes prior to the start of the meeting to log in. A stockholder must enter the control number that was provided in the Notice Regarding the Availability of Proxy Materials, proxy card or other proxy materials received by such stockholder in order to vote and ask questions that are germane to the business being discussed at the meeting.

A replay of the webcast will be available 24 hours after the meeting is concluded and will be archived on OraSure Technologies' website for seven days.

About OraSure Technologies

OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

Company Contacts:

Investor Contact:

Media Contact:

Sam Martin

Jeanne Mell

Argot Partners

OraSure Technologies, Inc.

(212) 600-1902

(484) 353-1575

orasure@argotpartners.com

media@orasure.com